Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30900413 | 0.85 | ELANE (0.33) | BUB1ELANEPIK3R1PIK3CACCNB2 | |
| SCHEMBL21075868 | 0.84 | BUB1 (0.34) | BUB1ELANEBCHE | |
| SCHEMBL29226355 | 0.80 | CUL4A (0.30) | — | |
| SCHEMBL22470779 | 0.79 | — | — | |
| SCHEMBL17837259 | 0.78 | USP30 (0.40) | BUB1 | |
| SCHEMBL21075867 | 0.77 | — | — | |
| SCHEMBL24837240 | 0.75 | — | — | |
| SCHEMBL17873707 | 0.74 | CDC7 (0.35) | BUB1 | |
| SCHEMBL17141679 | 0.74 | CDK1 (0.39) | BUB1CCNB2CDK1CCNB1GSK3B | |
| SCHEMBL25234196 | 0.74 | CDK1 (0.39) | BUB1CCNB2CDK1CCNB1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48635-E1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2021-07-13 | — | — | US | disclosed |
| US-RE48635-E1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200306254-A1 | COMBINATION OF ERK1/2 INHIBITOR COMPOUND WITH GEMCITABINE OR WITH GEMCITABINE AND NAB-PACLITAXEL FOR USE IN TREATMENT OF PANCREATIC CANCER | LILLY CO ELI (US) | 2020-10-01 | — | — | US | disclosed |
| US-20200306254-A1 | COMBINATION OF ERK1/2 INHIBITOR COMPOUND WITH GEMCITABINE OR WITH GEMCITABINE AND NAB-PACLITAXEL FOR USE IN TREATMENT OF PANCREATIC CANCER | LILLY CO ELI (US) | 2020-10-01 | — | — | US | disclosed |
| EP-3237423-B1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | LILLY CO ELI (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3237423-B1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | LILLY CO ELI (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3478292-A1 | COMBINATION OF ERK1/2 INHIBITOR COMPOUND WITH GEMCITABINE OR WITH GEMCITABINE AND NAB-PACLITAXEL FOR USE IN TREATMENT OF PANCREATIC CANCER | Eli Lilly and Company (US) | 2019-05-08 | — | — | EP | disclosed |
| US-9879029-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879029-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2018-01-30 | — | — | US | disclosed |
| WO-2018005234-A1 | COMBINATION OF ERK1/2 INHIBITOR COMPOUND WITH GEMCITABINE OR WITH GEMCITABINE AND NAB-PACLITAXEL FOR USE IN TREATMENT OF PANCREATIC CANCER | ELI LILLY AND COMPANY (US) | 2018-01-04 | — | — | WO | disclosed |
| US-9526733-B1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| US-9526733-B1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| US-9526733-B1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| US-9469652-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469652-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469652-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-10-18 | — | — | US | disclosed |
| WO-2016106029-A1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176896-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-06-23 | — | — | US | disclosed |
| US-20160176896-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-06-23 | — | — | US | disclosed |
| US-20160176896-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306254-A1 | COMBINATION OF ERK1/2 INHIBITOR COMPOUND WITH GEMCITABINE OR WITH GEMCITABINE AND NAB-PACLITAXEL FOR USE IN TREATMENT OF PANCREATIC CANCER | KRAS, MAPKAPK2, MAPK1 | BUB1 667/4885ELANE 2561/4885PIK3R1 492/4885 |
| US-20160176896-A1 | ERK INHIBITORS | MAPK4, MAPK1, MAPK3 | BUB1 491/4885ELANE 2518/4885PIK3R1 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.